Upstream Processing: Regulatory Considerations Regarding Quality Aspects of Monoclonal Antibodies - An alternative to the hybridoma method is producing engineered antibody molecules and fragments

ADVERTISEMENT

Upstream Processing: Regulatory Considerations Regarding Quality Aspects of Monoclonal Antibodies
An alternative to the hybridoma method is producing engineered antibody molecules and fragments by in vitro methods.


BioPharm International
Volume 20, Issue 7

35. http:// http://www.emea.eu.int/humandocs/Humans/EPAR/synagis/Synagis.htm [Accessed 2005 Oct 15].

36. http:// http://www.ebra.org/ebrabulletin-ecvam-report-monoclonal-antibody-production_76.htm [Accessed 2005 Sept 22].

37. http:// http://www.emea.info/humandocs/Humans/EPAR/leukoscan/leukoscan.htm; [Accessed 2005 Sept 23].

38. http:// http://www.emea.info/humandocs/PDFs/EPAR/Ceascan/041296en6.pdf; [Accessed 2005 Sept 22].

39. Marx U, Embleton MJ, Fischer R. Monoclonal antibody production. The report and recommendations of ECVAM workshop 23. 1997 ATLA 25:121-135.

40. Werner RG. The development and production of biopharmaceuticals. Bioprocess International 2005 Supplement to Vol. 3; 9:6-15.

41. http:// http://www.emea.eu.int/humandocs/Humans/EPAR/enbrel/enbrel.htm [Accessed 2005 Oct 11].

42. http:// http://www.emea.eu.int/humandocs/Humans/EPAR/humira/humira.htm; [Accessed 2005 Oct 14].

43. http:// http://www.emea.eu.int/humandocs/Humans/EPAR/herceptin/herceptin.htm; [Accessed 2005 Oct 15]

44. http:// http://www.preclinica.com/content/articles/frame.asp?issue=0304&article=12; [Accessed 2006, Oct 12]


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Launches Human Safety Study of Ebola Vaccine Candidate
August 29, 2014
Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
USP Awards Analytical Research
August 15, 2014
Author Guidelines
Source: BioPharm International,
Click here